|
|
|
Inhibition of angiogenesis by the tumour suppressor protein p53 may have a critical role in the progression of cardiac hypertrophy to cardiac failure, a paper published online by Nature suggests. Targeting this process may prove therapeutically useful.
When the heart struggles to pump blood around the body, it can compensate by becoming enlarged (hypertrophy). But prolonged cardiac hypertrophy can be fatal and lead to heart failure. Issei Komuro and colleagues studied a mouse model of cardiac hypertrophy. As the animals' hearts became enlarged, new blood vessels were seen to grow, supporting cardiac hypertrophy. But after about two weeks, p53 levels increased, angiogenesis was inhibited and the mice progressed to cardiac failure. The absence of p53 or the introduction of factors that stimulate angiogenesis prevented the progression from cardiac hypertrophy to heart failure. CONTACT Issei Komuro (Chiba University, Japan)
E-mail: komuro-tky@umin.ac.jp Abstract available online.
(C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|